PriceTargets.com logo

Madrigal Pharmaceuticals - MDGL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $347.33
  • Forecasted Upside: 10.92%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$313.15 As of 12/30/2024 01:08 PM ET
▲ +0.04 (0.01%)

This chart shows the closing price for MDGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Madrigal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDGL

Analyst Price Target is $347.33
▲ +10.92% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $347.33, with a high forecast of $441.00 and a low forecast of $150.00. The average price target represents a 10.92% upside from the last price of $313.15.

This chart shows the closing price for MDGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Madrigal Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/8/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/2/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/29/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024Cantor FitzgeraldReiterated RatingNeutral
11/5/2024B. RileyBoost TargetNeutral ➝ Neutral$194.00 ➝ $236.00
11/1/2024UBS GroupBoost TargetBuy ➝ Buy$411.00 ➝ $441.00
10/23/2024OppenheimerLower TargetOutperform ➝ Outperform$375.00 ➝ $350.00
10/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$390.00 ➝ $390.00
10/11/2024Cantor FitzgeraldReiterated RatingNeutral
8/8/2024CitigroupLower TargetBuy ➝ Buy$382.00 ➝ $371.00
8/8/2024Evercore ISILower TargetOutperform ➝ Outperform$405.00 ➝ $360.00
7/23/2024Cantor FitzgeraldReiterated RatingNeutral
7/16/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$381.00 ➝ $385.00
6/28/2024Cantor FitzgeraldInitiated CoverageNeutral
6/11/2024Wolfe ResearchInitiated CoverageOutperform$382.00
5/10/2024B. RileyLower TargetNeutral ➝ Neutral$270.00 ➝ $200.00
5/8/2024CitigroupLower TargetBuy ➝ Buy$389.00 ➝ $382.00
5/8/2024HC WainwrightLower TargetBuy ➝ Buy$425.00 ➝ $390.00
5/8/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$397.00 ➝ $381.00
4/22/2024Bank of AmericaInitiated CoverageUnderperform$150.00
3/20/2024Evercore ISIBoost TargetOutperform ➝ Outperform$325.00 ➝ $405.00
3/15/2024HC WainwrightBoost TargetBuy ➝ Buy$405.00 ➝ $425.00
3/15/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$338.00 ➝ $377.00
3/15/2024OppenheimerBoost TargetOutperform ➝ Outperform$320.00 ➝ $375.00
3/15/2024JMP SecuritiesBoost TargetOutperform ➝ Outperform$351.00 ➝ $397.00
3/15/2024CitigroupBoost TargetBuy ➝ Buy$382.00 ➝ $389.00
3/15/2024TD CowenBoost TargetOutperform ➝ Outperform$349.00 ➝ $390.00
3/15/2024UBS GroupBoost TargetBuy ➝ Buy$337.00 ➝ $410.00
3/15/2024B. RileyUpgradeSell ➝ Neutral$155.00 ➝ $270.00
3/14/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$336.00
3/6/2024CitigroupInitiated CoverageBuy$382.00
3/1/2024OppenheimerBoost TargetOutperform ➝ Outperform$300.00 ➝ $320.00
2/26/2024B. RileyDowngradeNeutral ➝ Sell$204.00 ➝ $155.00
2/23/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$347.00
2/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$347.00
1/24/2024Piper SandlerBoost TargetOverweight ➝ Overweight$305.00 ➝ $336.00
11/14/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$383.00
11/13/2023HC WainwrightBoost TargetBuy ➝ Buy$225.00 ➝ $275.00
9/19/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$325.00
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$225.00
9/11/2023B. RileyReiterated RatingNeutral ➝ Neutral$224.00
9/5/2023B. RileyReiterated RatingNeutral ➝ Neutral$224.00
8/9/2023OppenheimerLower TargetOutperform ➝ Outperform$350.00 ➝ $285.00
7/18/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$336.00
5/16/2023OppenheimerBoost Target$300.00 ➝ $350.00
2/28/2023Canaccord Genuity GroupBoost TargetBuy$296.00 ➝ $336.00
2/27/2023OppenheimerBoost TargetOutperform$250.00 ➝ $300.00
1/5/2023JMP SecuritiesBoost TargetMarket Outperform$312.00 ➝ $390.00
12/21/2022UBS GroupBoost TargetBuy$161.00 ➝ $337.00
12/20/2022Leerink PartnersBoost TargetOutperform$145.00 ➝ $315.00
12/20/2022Evercore ISIBoost Target$175.00 ➝ $325.00
12/20/2022CowenBoost Target$129.00 ➝ $309.00
12/20/2022OppenheimerBoost TargetOutperform$170.00 ➝ $250.00
12/19/2022JMP SecuritiesBoost TargetMarket Outperform$182.00 ➝ $312.00
12/19/2022Raymond JamesUpgradeUnderperform ➝ Market Perform
12/19/2022B. RileyBoost Target$75.00 ➝ $194.00
12/19/2022Piper SandlerBoost TargetOverweight$203.00 ➝ $280.00
12/19/2022HC WainwrightBoost TargetBuy$170.00 ➝ $225.00
12/19/2022The Goldman Sachs GroupBoost TargetBuy$178.00 ➝ $375.00
12/1/2022HC WainwrightReiterated RatingBuy
7/8/2022B. RileyDowngradeBuy ➝ Neutral$131.00 ➝ $75.00
5/12/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$133.00 ➝ $151.00
5/10/2022OppenheimerLower Target$180.00 ➝ $170.00
2/7/2022JMP SecuritiesReiterated RatingBuy$220.00
11/17/2021JMP SecuritiesReiterated RatingBuy$219.00
11/7/2021Evercore ISIInitiated CoverageBuy$199.00
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$151.00
8/11/2021HC WainwrightLower TargetBuy$184.00 ➝ $170.00
8/6/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform
8/6/2021BMO Capital MarketsLower TargetMarket Perform$134.00 ➝ $111.00
6/28/2021B. RileyReiterated RatingBuy
3/4/2021Chardan CapitalBoost TargetBuy$202.00 ➝ $203.00
3/2/2021OppenheimerLower TargetOutperform$200.00 ➝ $190.00
2/26/2021Chardan CapitalBoost TargetBuy$202.00 ➝ $203.00
11/23/2020Evercore ISIReiterated RatingOutperform$180.00
11/8/2020OppenheimerReiterated RatingBuy
11/6/2020Chardan CapitalReiterated RatingBuy$205.00
11/6/2020The Goldman Sachs GroupBoost TargetNeutral$118.00 ➝ $126.00
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$119.00 ➝ $124.00
11/6/2020HC WainwrightBoost TargetBuy$165.00 ➝ $184.00
11/5/2020Piper SandlerLower TargetOverweight$208.00 ➝ $204.00
8/6/2020OppenheimerReiterated RatingBuy$200.00
8/6/2020Stifel NicolausReiterated RatingHold$114.00
7/30/2020Piper SandlerInitiated CoverageOverweight$208.00
6/24/2020OppenheimerReiterated RatingBuy$200.00
6/4/2020BMO Capital MarketsInitiated CoverageMarket Perform$135.00
5/22/2020B. RileyBoost TargetBuy$134.00 ➝ $174.00
5/8/2020HC WainwrightLower TargetBuy$215.00 ➝ $168.00
5/7/2020Stifel NicolausReiterated RatingHold$116.00
5/5/2020Chardan CapitalInitiated CoverageBuy$205.00
4/15/2020B. RileyReiterated RatingBuy$134.00
4/14/2020Stifel NicolausReiterated RatingHold
3/5/2020CitigroupLower Target$166.00 ➝ $155.00
2/27/2020CowenReiterated RatingBuy
1/9/2020UBS GroupUpgradeNeutral ➝ Buy$125.00 ➝ $127.00
1/2/2020Leerink PartnersReiterated RatingOutperform
(Data available from 12/30/2019 forward)

News Sentiment Rating

1.51 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 18 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/3/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 14 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 16 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 12 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 24 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 18 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 18 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $313.15
Low: $306.02
High: $314.48

50 Day Range

MA: $301.00
Low: $202.48
High: $354.85

52 Week Range

Now: $313.15
Low: $168.25
High: $368.29

Volume

71,224 shs

Average Volume

431,590 shs

Market Capitalization

$6.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Madrigal Pharmaceuticals?

The following Wall Street research analysts have issued reports on Madrigal Pharmaceuticals in the last year: B. Riley, Bank of America Co., Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, StockNews.com, TD Cowen, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for MDGL.

What is the current price target for Madrigal Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Madrigal Pharmaceuticals in the last year. Their average twelve-month price target is $347.33, suggesting a possible upside of 10.9%. UBS Group AG has the highest price target set, predicting MDGL will reach $441.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $150.00 for Madrigal Pharmaceuticals in the next year.
View the latest price targets for MDGL.

What is the current consensus analyst rating for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals currently has 1 sell rating, 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MDGL.

What other companies compete with Madrigal Pharmaceuticals?

Other companies that are similar to Madrigal Pharmaceuticals include Biogen, United Therapeutics, Neurocrine Biosciences, Incyte and BioMarin Pharmaceutical. Learn More about companies similar to Madrigal Pharmaceuticals.

How do I contact Madrigal Pharmaceuticals' investor relations team?

Madrigal Pharmaceuticals' physical mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company's listed phone number is (267) 824-2827 and its investor relations email address is [email protected]. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. Learn More about contacing Madrigal Pharmaceuticals investor relations.